GlaxoSmithKline's Contract Manufacturing Delays Cause Shortage of Restless Leg Treatment

The FDA announced a shortage of Horizant (gabapentin enacarbil; GlaxoSmithKline) 600mg extended-release tablets. Horizant is a prodrug of gabapentin that is indicated for postherpetic neuralgia and for moderate-to-severe primary restless legs syndrome in adults. GlaxoSmithKline is currently experiencing a backorder situation. XenoPort will assume manufacturing and commercialization of Horizant from May 1, 2013. XenoPort anticipates the Horizant shortage to extend into June 2013.